FAX RECEIVED

GROUP 1600



## FACSIMILE TRANSMITTAL

from HOLLY D. KOZLOWSKI

February 26, 2003

Direct: 513-977-8568 / Fax: 513-977-8141 / holly.kozlowski@dinslaw.com

To:

Examiner A. Pulliam

Firm:

USPTO, GAU 1615

Fax Number:

1-703-305-3592

Client Number:

10914-11

Pages:

(including cover)

15

OFFICIAL

Comments:

If there are any problems in receiving this transmission, please call the fax room at (513) 977-8483 immediately. Thank you.

## Notice

This message is intended only for the use of the individuals or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this notice is not the intended recipient or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this notice in error, please notify us immediately by telephone and return these papers to us at the address below via first class mail.

Cincinnati • 1900 Chemed Center • 255 East Fifth Street • Cincinnati, OH 45202 • Phone: (513) 977-8200

FEB 26. 2003 4:18PM

P. 4/15 NO. 2510

Docket No. 10914-11

CERTIFICATE OF FACSIMILE

I hereby certify that this paper is being transmitted via facsimile to Group Art Unit 1615; Box AF; Commissioner of Patents, Washington, DC 20231 at facsimile number 703/305-3592

on February 26, 2003.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant:

Isa Odidi et al

Paper No.:

Serial No.:

09/403,437

Group Art Unit:

1615

Filed: October 21, 1999

Examiner:

A. Pulliam

For:

Controlled Release Formulations Using Intelligent Polymers

## AMENDMENT UNDER 37 CFR 1.116

Box AF Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the Official Action dated November 18, 2002 and the Advisory Action dated February 10, 2003, please amend the present application as follows:

In the Claims:

Please cancel claim 4.

Please amend claims 1, 14, 25, 30, 33 and 34 to read as follows:

(Fifth Amendment) A controlled release pharmaceutical composition 1.

comprising:

at least one pharmaceutically active substance having a water contact angle (a)

( $\theta$ ) such that  $\cos \theta$  is between 40.9848 and -0.9848;

a first intelligent polymer component; and (b)

a second intelligent polymer component having opposite wettability (c)

characteristics to said first intelligent polymer component, said second intelligent polymer